Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...
This is the first FDA approval of targeted therapy for pediatric patients <12 years of age with RET alterations. Selpercatinib was previously granted accelerated approval for thyroid cancer ...
Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...
MTC patients who were initiated on RETi between 2018 and 2022 were included. Baseline characteristics, RET mutational status, RETi response, available tumor tissue and molecular profiles sampled pre- ...
Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions. The Food and Drug Administration (FDA) granted an accelerated approval to ...
Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort MTC patients who were initiated on RETi between 2018 and 2022 were included. Baseline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback